Biogen’s aducanumab shoulders sector’s pipeline hopes, again
Celgene's CAR-T and Glaxosmithkline's antibody-drug conjugate are among the industry's most valuable R&D assets.
Most valuable unpartnered assets reveal a changing of the guard
Annual analysis shows a new crop of biotech assets with ballooning valuations and no major partners.
Pharma’s fastest followers revealed
Analysis of me-too drug approvals over time shows trends across therapy areas.
Big pharma proves that oncology pays as workforces shrink
Bristol-Myers Squibb has come out on top of an analysis of efficiency in big pharma. Being in immuno-oncology might have helped – but so might aggressive job cuts.
The big launches of 2014 – where are they now?
The drugs of 2014 that went supernova and those that failed to make orbit.
Shifting forecasts reveal the winners and losers of 2017
Gilead and Abbvie feel the heat as forecasts shrink for their top drugs, while Biogen's Spinraza exceeds expectations.
Buyers of cancer assets fan the licensing deal market
The price of early stage cancer assets leaves Celgene shelling out $3.5bn in upfront payments, with no end in sight for rising valuations.
Deal hungry biopharma remains happy to pay up
As companies retreat from M&A licensing deal valuations hit new peak.
The sector’s most valuable unpartnered assets – up for grabs or on the shelf?
Pharma companies have passed on in-licensing drugs such as Kite Pharma’s CAR-T therapy and Incyte’s IDO inhibitor. Do they know something?
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.